Second Genome, Inc.

Industry

  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Technologies
      • Genomics-Proteomics
    • Large Molecule
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Digital Health
  • Pharmaceuticals
    • Vaccines
  • Services
See more in Biomedtracker

Latest on Second Genome, Inc.

Scrip

Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs

 
• By Joseph Haas, Ian Haydock, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Alnylam And Dicerna Team Up

Scrip

Gilead Moves Into Microbiome In Deal With Second Genome

 
• By Joseph Haas

Gilead Sciences Inc. has been looking for a way into microbiome research for a while, and following a competitive process, settled on a four-year collaboration with Second Genome Inc. to identify b

Scrip

Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea

 
• By Jung Won Shin

Amid a global boom in microbiome drug development in recent years, industry interest, R&D, and investment in this promising new therapeutic sector is also rising in South Korea. KoBioLabs Inc., founde

Scrip

Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer

 
• By Joseph Haas and John Davis

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Deerfiel